Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients with moderate to severe chronic plaque-type psoriasis

Next Previous
Search
Trial Profile

A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel in patients with moderate to severe chronic plaque-type psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms EGALITY
  • Sponsors HEXAL; Sandoz

Most Recent Events

  • 17 Nov 2017 According to a Sandoz Canada media release, Erelzi has been granted Health Canada approval in April 2017. The approval was based on a comprehensive development program consisting of comparative analytical, preclinical, and clinical data including this trial.
  • 27 Jun 2017 According to a Sandoz media release, the European Commission (EC) has approved Erelzi for use in Europe. Erelzi is approved for use in all indications of the reference medicine, Enbrel. The approval was based on a comprehensive development program generating analytical, preclinical, and clinical studies including this trial.
  • 21 Apr 2017 According to a Sandoz media release, the Committee for Medicinal Products for Human Use (CHMP) of EMA has adopted positive opinion recommending approval of biosimilar etanercept to treat the same indications as the reference product (Enbrel). The recommendation was based on results from biosimilar development program that included this trial.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top